evonetix stock symbol
Oversubscribed round led by Foresite Capital; Funding will enable development of DNA synthesis chip technology to commercial scale; EVONETIX LTD ('Evonetix'), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB 44 million). information on technology stack, industry listing, and other details. Professor Sir David Klenerman is Professor of Biophysical Chemistry at the University of Cambridge, where he also earned his PhD. Iridia is developing a DNA-based data storage solution. Evonetixs proprietary process utilises a novel silicon chip to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or pixels, on the chip surface. Investors. Win whats next. As a part of the partnership, Zaptic, and Molten Ventures will work together to scale the formers solution to help 700 million industrial workers across global supply chains, to operate flawlessly. Look at Evonetix's recent job hiring categories, identify which sector is rapidly growing, Read more, Find prospects by the technologies they use. Live from Dubai, connecting Asian markets to the European opens. He works with some of Cambridge Consultants largest clients, helping them maximise the value of innovation. April 23, 2023 06:50 am EDT. Funding will enable development of DNA synthesis chip technology to commercial scale. He works across a broad range of sectors from telecommunications to consumer products, focusing on the impact of digital platforms to enable new business models. Log in Subscribe Evonetix Raises $24M in Extended Series B Funding Round . He holds a masters degree in electronic systems engineering from the University of York and is a Fellow of the Institution of Engineering and Technology. Round. The company aims to introduce a biochemical process for DNA and RNA synthesis based on the use of efficient enzymes. Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. Developer of instrumentation for gene synthesis analysis. These roles have given Malcolm experience of developing companies as they grow in size and complexity. Zyme Communications Jason was CEO and editor in chief of MIT Technology Review and editor of Red Herring magazine, the bible of the dot.com boom. With this round, the total investment raised by Zaptic accounts for $16 million. He still writes, mostly for WIRED. By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridia is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density. Matthew specialises in multi-disciplinary system design, medical device development, ASIC design and opto-electronics. Over the last decade he has championed deals across areas including diagnostics, devices & biotech. To find emails, direct dials, and more for prospects across the web. evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA. Learn more. You can read more about your cookie choices at our privacy policyhere. Date. Bloomberg Daybreak Middle East. 2/7/2023. CBI websites generally use certain cookies to enable better interactions with our sites and services. Error detection during hybridisation of target double-stranded nucleic acid, UK-based Zaptic raises $10M to develop connected platform for frontline workers, SynBioBeta's Reading, Writing & Editing DNA Digest, The enzymatic DNA synthesis market is expected to grow from US$ 240.96 million in 2022 to US$ 2,244.88 million by 2028; it is estimated to record a CAGR of 45.1% from 2022 to 2028, Enzymatic DNA Synthesis Market Worth $2.24 Billion, by 2028 with 45.1% CAGR Global Report by The Insight Partners, Gene Synthesis Market Size, Share & Trends Analysis Report By Method, By Service, By Application, By End-use, By Region And Segment Forecasts, 2023 - 2030. Equity securities are offered through EquityZen Securities. He focussed on Programme and Line Management in the UK before taking a secondment to the US to lead the expansion of the Boston site into Industrial and Consumer. The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZens platform. Before that, Trevor held roles as EDA Partner Manager at ARM Holdings, Director of Operations for Samsung Electronics and Director of Programme Management at CSR. He has written for a range of publications including a column for the New York Times and articles for many other newspapers and magazines like The Economist, The Financial Times, The Boston Globe and The Believer. For specific trademark information, see www.evonetix.com/legal, Today is National #DNA Day! Prior to this, Mammen was an Executive Director and Regional Finance Director for the Asian business operations of Arthur D Little. United Kingdom. Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. You can read more about your. The machine creates DNA primers, a short single strand of RNA or DNA (generally about 18-22 bases) that serves as a starting point for DNA synthesis. 2023 PitchBook. EVONETIX LTD ('Evonetix'), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. CAMBRIDGE, United Kingdom-- ( BUSINESS WIRE )--EVONETIX LTD ('Evonetix'), the synthetic biology company developing a desktop platform for . affect the user interaction and engagement with the company. The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Copy and paste multiple symbols separated by . He is currently on the boards of Horizon Discovery PLC and EcoEos. KioBaser is building what it dubs "Nespresso machine of DNA synthesis". Mammen graduated with a first class degree in Commerce from the University of Madras, India. At the core of this is the ability to deliver DNA better and faster to researchers working on these global challenges. Morningside Group was founded in 1986 by the Chan family of Hong Kong, to make private equity and venture capital investments. He completed his PhD at the University of Cambridge. In 2012, he became a Fellow of the Royal Society in recognition of his contribution to the translation of science into business, in 2013 a Distinguished Fellow of BCS, the Chartered Institute for IT, and in 2015 an Honorary Knight Commander (KBE) for services to engineering and industry. February 7, 2023 10:51 PM UTC. This investment from Molten Ventures will allow us to scale our business to meet that demand and continue to invest deeply into creating an operational knowledge layer for workers, with operational data enabled by AI. He was the first investor in DCVC-backed Totus Medicines, where he is a founding board member, and in Menten.AI. The top technologies used by Evonetix are Let's dig . By digitising processes and making knowledge more accessible to frontline workers, Zaptic is helping manufacturers significantly improve productivity, reduce waste and better meet customer demands. Before that, Trevor held roles as EDA Partner Manager at ARM Holdings, Director of Operations for Samsung Electronics and Director of Programme Management at CSR. site you are consenting to these choices. Privacy Act (CCPA), please email [emailprotected]. He primarily operated from a base in Singapore. Colin McCracken, CEO of Evonetix added: "Biology is driving a revolution that will change the way we live and help solve some of the biggest problems faced by our planet today. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. By continuing to use this site you are consenting to these choices. Investors of Evonetix include Cambridge Consultants, Morningside Ventures, Molten Ventures, DCVC, Civilization Ventures and 7 more. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Java clicking here. Malcolm is responsible for a broad portfolio of financial, HR and other matters. Foresite Capital has a uniquely collaborative investment model that benefits from insights generated by its multidisciplinary team of scientists, clinicians, investment analysts and engineers. Build a competitive intelligence sales and marketing strategy based on the data and stand out in the market. He has also held board positions at Psynova Neurotech, Bioscale and Enigma Diagnostics. He works with some of Cambridge Consultants largest clients, helping them maximise the value of innovation. Malcolm has worked globally (being based in the UK and Australia) and also across a range of industries. Get the full list, Youre viewing 5 of 11 investors. Colin brings over 20 years experience in commercial and business development roles. She also acted as a Consultant for projects in collaboration with Genomics England, Technology Development and Applications, and Customer Support. Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. She then moved to leadership roles of global multidisciplinary projects to support product development and introduction of new products. lorna.cuddon@zymecommunications.com, Internet Explorer presents a security risk. Evonetix recently closed $24 million financing in an oversubscribed round led by Foresite Capital. He is currently on the boards of Horizon Discovery PLC and EcoEos. Workers need on-the-job assistance in knowing what to do, when to do it, and how best to do it at the point of use. March 02, 2020 02:00 AM Eastern Standard Time. Evonetix's proprietary process utilises a novel silicon chip to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or 'pixels', on the chip . He is always looking for visionaries: men and women with insights into therapeutics, devices, diagnostics or services that could, with the right support, change the world. In 40 year career as an entrepreneur and venture capitalist, Hermann has helped start a number of technology companies, including Acorn Computers and its spin-out ARM, as well as Cambridge Silicon Radio and next-generation DNA sequencing technology company Solexa, which became the market leader and was later acquired by Illumina. At TED 2013, he delivered a Talk, Can technology solve our big problems? which has been seen 1.6 million times. Malcolm joined Evonetix in June 2021 with over 20 years of experience. Evonetix Ltd | 3,339 followers on LinkedIn. In a highly competitive market, manufacturers need to enable their workforce to flex across new equipment, processes, and products, with a heavy focus on the alignment of people and data. DCVC and its principals have supported brilliant people changing global-scale businesses for over twenty years, helping create tens of billions of dollars of wealth while also making the world a markedly better place. Combined with the Companys patented chemistry, this approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA, addressing the DNA supply bottleneck in the field of synthetic biology. Blood stem cell company Garuda Therapeutics Inc. has raised $62 million in a series B round led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management and Aisling Capital. Evonetix is ready to meet these challenges and open the door to the exciting next phase of our development., To apply to be included in the early access program, please visit: www.evonetix.com/access, View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005493/en/, Lorna Cuddon Evonetixs proprietary process utilises a novel silicon chip to control the synthesis of DNA at many thousands of independent thermally controlled reaction sites, or pixels, on the chip surface. Building a platform capable of this requires highly parallel, distributed synthesis. Hermann was awarded an Honorary CBE for innovative service to the UK enterprise sector in 2001. You can read more about your. These roles have given Malcolm experience of developing companies as they grow in size and complexity. Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions. Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with applications across industries including healthcare, pharma, biotech, food and agriculture, and data storage. The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. 1. Before joining Evonetix, Matthew was Head of Technology for the Global Medtech Division of Cambridge Consultants. CAMBRIDGE, England, February 07, 2023--(BUSINESS WIRE)--EVONETIX LTD (Evonetix), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB 44 million). Excludes vitamins/supplements, CROs/clinical trial services. The Company has raised $30 million USD (23 million GBP) in this round, which was led by new investor Foresite Capital. CBI websites generally use certain cookies to enable better interactions with. Jason Pontin is a Partner at DCVC, where his belief that emerging technologies and new scientific insights can solve urgent challenges and expand human possibilities inspires his investments in Deep Tech and life sciences companies. Evonetix Closes $24 Million USD (20 Million) Financing CAMBRIDGE, England--(BUSINESS WIRE)--EVONETIX LTD ('Evonetix'), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB 44 million). Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data. Evonetix has raised $24 million to develop technology that assembles long strands of DNA on silicon chips using phosphoramidite chemistry. Evonetix headquarters are at Previously, Vishal worked at Atlas Venture, The Wellcome Trust and Radiant Capital. We use cookies to optimise our website and our service. Evonetix brings together the talents of an astonishing group of scientists and engineers, across biology, physics, electronics, chemistry, software and mechanics; all with the same mission, to unlock the capabilities of semiconductor technology for the world of synthetic biology. Building a platform capable of this requires highly parallel, distributed synthesis. The shares are up nearly 300% since the start of 2020, while the . By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Zyme Communications Evonetix is in a very exciting phase, having recently opened our early access program. It applies a rigorous scientific and data-driven approach to investment analysis. He was the first investor in DCVC-backed Totus Medicines, where he is a founding board member, and in Menten.AI. At MIT, he founded MIT Solve, the Institutes open innovation platform, which deploys capital and other resources toward solutions to grand challenges; chaired the MIT Enterprise Forum, the Institutes global entrepreneurial community; and was senior advisor to MITs 16th President, Susan Hockfield. Find useful insights on Evonetix's company details, tech stack, news alerts, competitors and more. She then moved to leadership roles of global multidisciplinary projects to support product development and introduction of new products. Investors must be able to afford the loss of their entire investment. Professor Andrew Briggs is Professor of Nanomaterials at the University of Oxford, where his research focuses on materials and techniques for quantum information technologies and investigating vibrational states of nanotubes and charge transport through single molecules in graphene nanogaps. Civilization Ventures leverages an extensive network of world-class scientists and clinicians (including half a dozen MDs and PhDs), as well as accomplished founders and CEOs from our portfolio companies, to gain access to and understand the leading innovations in our space. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing) and advanced agricultural and industrial products, through gene development and DNA-based data storage. +0.83%. At MIT, he founded MIT Solve, the Institutes open innovation platform, which deploys capital and other resources toward solutions to grand challenges; chaired the MIT Enterprise Forum, the Institutes global entrepreneurial community; and was senior advisor to MITs 16th President, Susan Hockfield. The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. The company develops a DNA and RNA synthesizer for molecular biology research purposes.